ventilator-associated pneumonia
Better Tools for Fighting Gram-Negative Infections, but More Are Needed
Multidrug-resistant gram-negative bacteria are difficult to treat, but FDA approvals have increased the clinical ...
FEBRUARY 27, 2025
Attacking the ‘Slime’ Could Improve VAP Care
Biofilms make it harder to treat ventilator-associated pneumonias.
SEPTEMBER 13, 2024
How Much Do We Know About Non-Ventilator HAP?
Better prevention of NV-HAP, the authors said, would improve patient care worldwide, while saving health systems ...
SEPTEMBER 13, 2024
Right Drug for the HABP and VABP Patient
Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia are among the most common and ...
AUGUST 23, 2023
FDA Grants HABP/VABP Indication for Zerbaxa
The FDA approved a new indication for ceftolozane-tazobactam to treat hospital-acquired bacterial pneumonia and ...
JUNE 3, 2019
Merck to Seek New Indication for Zerbaxa
Zerbaxa is being studied for hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia ...
SEPTEMBER 18, 2018
Use Short Courses of Antibiotics To Treat HAP and VAP
HAP and VAP account for 20% to 25% of hospital-acquired infections, and may be fatal 10% to 15% of the time.
JULY 15, 2016
